Rick Simpson Oil (RSO) in New Zealand: The Complete Guide by OilWell Cannabis

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For Kiwis watching from the other side of the world, this story hits familiar notes. We’ve all seen mates let down by the system—whether it’s a shearer with chronic back pain after years in the woolshed, a forestry worker dealing with post-injury complications, or a cancer patient told there are no more options through the public health queue. The frustration with institutional medicine resonates deeply here in Aotearoa.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, the medications he was prescribed either failed to help or made things worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference in Simpson’s advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment came in 2003. He reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up exists in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil .

Important context: Simpson’s account is presented as his personal testimony. The absence of clinical documentation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement around concentrated cannabis oil—one that would eventually reach communities across New Zealand, from Northland to Southland.

The crusade—spreading the oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community, charging nothing. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others .

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. It documented his claims, showed testimonials from people he’d treated, and framed his work as a grassroots challenge to pharmaceutical interests. Within cannabis communities, it was foundational—for many, Run From The Cure was their introduction to concentrated cannabis oil as medicine .

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and again in 2009. He was charged with cannabis cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, continuing his advocacy from Croatia and later the Netherlands .

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his experience, oil-making process, and philosophical views .

Throughout his public career, Simpson maintained that cannabis oil—particularly high-THC oil made his way—could cure cancer and many other diseases, and that pharmaceutical companies and government agencies were actively suppressing this knowledge .

Important context: Simpson’s conspiratorial framing is noted without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. For Kiwis who’ve watched debates about Pharmac funding, medical cannabis access, and institutional delays, this skepticism toward centralized systems feels familiar.

The traditional RSO protocol—Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol delivering 60 grams of concentrated cannabis oil over roughly 90 days. He described it as a cancer treatment protocol, though he recommended it for numerous other conditions .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum necessary for serious cancer treatment.

Titration schedule

• Week 1: Begin with a dose about half a grain of rice—roughly 10-15mg of oil—three times daily (morning, afternoon, before bed). Total daily intake: ~30-45mg. Simpson emphasized starting small to allow the body to adjust to THC’s psychoactive effects.

• Weeks 2-5: Double the dose every four days. The slow ramp-up builds THC tolerance gradually. By week 4-5, target ~1 gram (1,000mg) of oil daily, divided into three doses.

• Weeks 5-12: Maintain ~1 gram daily, divided into three 333mg doses, until all 60 grams are consumed.

Administration methods

• Primary method—oral: Simpson recommended sublingual or swallowing. He considered oral ingestion essential for systemic absorption and primary treatment for internal cancers.
• Secondary—topical: For skin cancers, apply oil directly, cover with bandage, change every 3-4 days. Combine with oral dosing.
• Not primary—inhalation: Simpson acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained oral route was necessary for sustained, high-dose exposure.

Tolerance and psychoactive effects

• Simpson maintained patients develop significant tolerance to THC’s psychoactive effects within 3-4 weeks of consistent dosing.
• He viewed euphoric, sedating, or disorienting effects as minor and temporary, urging patients not to let the high discourage continuation.
• Recommended initial doses at night to sleep through intense early effects.
• Warned against driving or operating machinery during titration.

Post-protocol maintenance

After completing 60 grams, Simpson recommended maintenance dosing of 1-2 grams monthly, indefinitely, for long-term health and cancer prevention.

Dietary and lifestyle recommendations

Simpson advocated dietary changes—reducing sugar, avoiding processed foods, improving nutrition—though this was secondary and general compared to his detailed oil protocol.

Important context for evaluating this protocol

This protocol was designed by one person based on personal experience, not clinical trials, dose-finding studies, or formal research. Critical points:

• No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing, patients consumed ~1 gram of high-THC oil daily. Assuming 60-90% THC, this translates to ~600-900mg delta-9 THC daily—far exceeding anything studied clinically. For context, FDA-approved dronabinol is typically dosed at 2.5-20mg daily.
• Real risks at these doses. Consuming 600-900mg THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as primary treatment—potentially in place of proven therapies—introduces harm beyond the oil itself.

For Kiwis considering this protocol, it’s crucial to consult with your oncologist, GP, or a cannabis-informed clinician. New Zealand’s cancer treatment centers—like those at Auckland City Hospital, Wellington Regional Hospital, or Christchurch Hospital—offer evidence-based care that should form the foundation of any cancer strategy. RSO may be considered complementary, never replacement.

What is traditional Rick Simpson Oil—the product

Traditional RSO refers to the specific oil Simpson made and advocated for, defined by his method and materials .

Source material

Simpson used high-THC, indica-dominant cannabis strains. He favored heavy, sedating indica genetics and generally recommended against sativa for cancer treatment. He grew his own or sourced from trusted growers. There was no strain standardization—starting material varied by availability and season.

Extraction solvent

Simpson originally used naphtha (a petroleum-based solvent, commercially available as lighter fluid), later also endorsing 99% isopropyl alcohol. He warned against butane or acetone. Neither naphtha nor isopropyl alcohol is food-grade—a significant safety issue.

Extraction process

1. Dry or semi-dry cannabis in a container (typically a bucket).
2. Cover with solvent, agitate several minutes to dissolve cannabinoids.
3. Pour solvent through filter (cheesecloth) into collection vessel.
4. Repeat with fresh solvent on same plant material.
5. Combine solvent washes—dark, cannabinoid-rich liquid.
6. Place in rice cooker or open vessel. Evaporate solvent at relatively low heat. Simpson recommended rice cooker because it maintains temperature that evaporates solvent without exceeding cannabinoid degradation thresholds—though still high enough to decarboxylate THCa into THC and destroy most volatile terpenes.
7. As solvent evaporates, thick, dark oil remains.
8. Transfer final oil into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was extremely dark—nearly black—thick, viscous, tar-like oil. Strong cannabis odor, possible faint solvent-residual smell depending on purging thoroughness. Sticky and difficult to handle at room temperature, more fluid when warmed.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. Heat converted essentially all THCa into delta-9 THC. Traditional RSO was activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG the source strain contained were present at natural ratios, but not controlled, measured, or targeted.
• No ratio control. Profile entirely determined by genetics and growing conditions.
• Estimated THC content. Likely ranged from ~60-90% total THC by weight, never lab-verified in traditional production.

Terpene content

Minimal to none. Solvent extraction dissolved terpenes, and high-heat evaporation volatilized them (most boil below 180°C). Traditional RSO was effectively terpene-free, despite being derived from terpene-rich plant.

Standardization and testing

None. Every batch was different—dependent on starting material, growing conditions, solvent purity, extraction technique, evaporation temperature/duration, and maker’s process. Simpson operated before cannabis legalization and standardized lab-testing infrastructure. No Certificate of Analysis, cannabinoid quantification, or contaminant screening.

Residual solvent risk

Most significant safety concern. Naphtha is complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene—compounds with established toxicity. Isopropyl alcohol, while cleaner, isn’t intended for internal consumption. Incomplete solvent purging—difficult to verify without analytical chemistry—leaves potentially harmful residues.

Modern extraction uses food-grade ethanol or supercritical CO₂, allowing more complete solvent removal and testing for residuals via validated methods like headspace gas chromatography. This is one of the most straightforward improvements modern regulated industry made over traditional RSO.

For Kiwis considering DIY extraction: New Zealand’s fire safety regulations, apartment living density in Auckland and Wellington, and the country’s strict consumer protection standards make traditional solvent-based methods particularly risky. The Fire and Emergency NZ guidelines on flammable liquids apply directly to home extraction attempts.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims—RSO could cure cancer and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and more. He was adamant, consistent, and public about these claims throughout his advocacy career .

Evaluating these claims against actual evidence using same standards applied throughout this document is important.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. Never submitted results to peer review. His evidence base consisted of personal experience, self-reported patient outcomes, and informal testimonials—with no controls, independent verification, imaging confirmation, long-term follow-up, or blinding.

What the preclinical literature shows

Preclinical cannabinoid-cancer literature exists and is scientifically interesting:

• In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal model studies show some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings generate legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human clinical outcomes is vast, well-documented across oncology research, especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, and have not produced results supporting cancer-cure claims .

For Kiwis navigating cancer treatment, organizations like the Cancer Society of New Zealand, BCAC (Breast Cancer Aotearoa Coalition), and local oncology departments provide evidence-based care. While preclinical research is promising, it shouldn’t replace proven treatments available through our healthcare system.

Institutional positions

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in lab and animal models but does not endorse cannabis or cannabis oil as cancer treatment .
• U.S. Food and Drug Administration (FDA): Has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid-related products are for specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada: Has never approved RSO or cannabis oil as cancer cure.
• NCCIH: Explicitly states strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and appetite-related indications in HIV/AIDS—not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as serious biomedical research area when world was ignoring or suppressing conversation. His advocacy—however scientifically imprecise—helped create political, cultural, and social conditions for legal cannabis industry and cannabinoid research infrastructure existing today. He was among first to bring concentrated cannabis oil to widespread public awareness, and term RSO remains most recognized name for full-spectrum cannabis extract in consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is documented concern in alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from personal-experience perspective, exceeded what evidence could support and still exceeds it today.

The legacy of Rick Simpson and evolution of modern RSO

Term RSO is now used broadly and often loosely across legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract in syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. Term has become generic .

Simpson himself has been critical of commercial products using RSO name while departing significantly from his original method and philosophy. He has publicly stated many products sold as RSO don’t meet his standards and commercialization contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave oil away free and urged people to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in DIY, free-access model where anyone could grow cannabis, extract oil, and treat themselves without corporate or governmental intermediaries. Modern cannabis industry has done something very different: commercialized, standardized, and regulated what Simpson distributed free. Whether that evolution represents improvement (through quality control, lab testing, dosing precision) or betrayal (through profit extraction and regulatory gatekeeping) depends on perspective, and cannabis community remains divided.

What is not disputed is modern RSO has evolved substantially from origins, and those changes are directly relevant to formulas in this document.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available/ performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by RSO tradition but depart deliberately in evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5% with specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

• THCa as separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as distinct ingredient, preserving acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60-90% of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects broader cannabinoid research landscape rather than single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: oral oil from syringe. OilWell offers both 30 mL sublingual oil and 1-gram vape cartridge, each with format-specific formulation acknowledging different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene—compounds with established toxicity. Incomplete solvent purging—difficult to verify without analytical chemistry—leaves potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical CO₂. These allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography. This is one of most straightforward improvements modern regulated industry made over traditional RSO production model.

This evolution connects directly to product-quality discussion in GENERAL KNOWLEDGE section, which emphasizes product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

For Kiwis, this is particularly relevant. New Zealand’s consumer protection standards are robust, and our history with contaminated products (like the 2008 melamine scandal) has made us wary. Knowing your RSO is solvent-free and third-party tested isn’t just a feature—it’s essential peace of mind.

The decarboxylation question

Traditional RSO was fully decarboxylated. Heat involved in evaporating solvent from rice cooker—typically sustained at or near solvent’s boiling point (naphtha ~60-80°C, isopropyl alcohol ~82°C)—was sufficient to convert essentially all THCa in extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over durations involved in solvent evaporation.

As result, acidic cannabinoids that exist abundantly in raw cannabis plant material—including THCa, CBDa, CBGa—were lost as distinct compounds in traditional RSO. Finished oil was decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as separate ingredient. This is intentional formulation choice informed by THCa evidence profile in GENERAL KNOWLEDGE section, which notes THCa itself does not produce psychoactive effects associated with THC but interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

For New Zealand customers, this means you have a choice that Simpson’s original recipe never offered. You can use the oil raw for daytime anti-inflammatory benefits without impairment, or decarboxylate it at home for full psychoactive potency. That flexibility matters for Kiwi lifestyle—whether you’re working in the trades, managing a business, or caring for whānau.

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin volatilizing at temperatures between 21 and 157°C, with many abundant terpenes—including myrcene, limonene, pinene—having boiling points below 180°C. Traditional RSO production destroyed terpenes two ways: dissolving them into solvent wash along with cannabinoids, then evaporating them off during high-heat solvent-removal phase.

This meant traditional RSO was essentially cannabinoid-only product, despite being derived from terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5% with defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile discussed in GENERAL KNOWLEDGE section. Entourage-effect literature [20][29] provides theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence standards then and now

Rick Simpson operated in pre-legalization, pre-lab-testing era. When he began making and distributing oil in early 2000s, cannabis was illegal in Canada and most of world. No regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, no peer-reviewed journals dedicated to cannabis therapeutics. Cannabis underground was only access point, and personal experience was primary evidence currency.

Simpson’s methods reflected constraints of that era. His evidence was anecdotal. Production was unstandardized. Claims were untested in formal sense. This is not necessarily moral failing—it is description of environment in which he operated.

This document takes fundamentally different approach. GENERAL KNOWLEDGE section applies formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. Intent is to honor historical origin of RSO while committing to standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

For Kiwis navigating this space, this approach matters. We have strong research institutions—University of Otago’s cannabis research, Auckland University’s clinical trials, NZ’s own medical journals. The evidence hierarchy used here aligns with how our medical community evaluates treatments.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison between Simpson’s dosing recommendations and dosing with modern, standardized, multi-cannabinoid formulation is not straightforward—products are fundamentally different.

Key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was ~60-90% delta-9 THC. OilWell’s formula distributes 16,590 mg total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak delivered ~600-900 mg delta-9 THC daily. OilWell’s sublingual formula contains only 90 mg delta-9 THC in entire 30 mL bottle (3 mg/mL), making per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence in GENERAL KNOWLEDGE section and responsible titration principles accounting for safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations—that work requires its own development process and should incorporate safety considerations documented throughout this file.

For New Zealand users, this means OilWell’s products require their own approach. If you’re working with a cannabis clinic in Auckland, pain specialist in Wellington, or GP in Christchurch who understands cannabinoids, they can help develop a personalized protocol based on this modern formulation—not Simpson’s historic but unvalidated method.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas—a city more than 7,000 kilometers from Auckland, but connected to New Zealand through shared values of resilience, innovation, and community. Colin grew up in McAllen, Texas, right across the river from Reynosa, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the US-Mexico border. It’s a place where survival requires grit, where mates are family, and where you learn to hustle not for profit, but to stay alive.

Colin’s childhood was marked by exposure to both opportunities and challenges of life along the border. Early on, he learned to hustle, taking on risky work transporting items across the border for various groups. Those experiences exposed him to complexities and dangers of that region. A lot of his best mates have been killed or are in prison because of associated dangers. He’s faced every form of violence imaginable, both in streets and across border. By sixteen, one way or another, he had to leave home for good.

Despite dangers, Colin didn’t fall into darkest paths available, like selling harder substances. Instead, he focused on cannabis, seeing it as safer and more beneficial alternative. He grew up in traditional cannabis world long before legalization, learning plant intimately while operating in shadows. Over time, he transitioned from those early, risky ventures to creating legal, legitimate business in industry he believes in.

Colin later became formally trained software engineer and did custom development work for Baylor College of Medicine, one of most prestigious medical institutions in Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

Bentley’s story—the heart of OilWell

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through toughest times. When Bentley fell seriously ill, veterinarians delivered verdict no pet owner wants: euthanasia was only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more pain and suffering. Choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley wasn’t option. Colin had already faced too much loss and seen too much suffering. Bentley was fighter, just like him, and Colin wasn’t ready to let him go. In desperate search for alternatives, he stumbled upon healing properties of CBD—through question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He’d never explored therapeutic and medicinal applications. Jessica’s question exposed blind spot that would become mission.

Determined to save Bentley, Colin learned to create CBD golden paste—specialized cannabinoid formula for pets. It wasn’t cure, but it was lifeline—and hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was miracle. From paralyzed facing euthanasia to fetching his ball. This wasn’t placebo effect—dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into world of cannabis beyond just getting high. It became mission to create real solutions that help alleviate pain and suffering, not just for pets but for people. Bentley’s story is foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin’s personal battle—PTSD, benzo addiction, and Peace Gummies

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using cannabinoid knowledge he’d developed keeping Bentley alive. The Peace Gummies formula that became OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies formula in vape form, which Colin personally uses to manage his insomnia and severe PTSD ongoing. This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery that cannabinoids work when pills do not.

For New Zealand’s veteran community—those who’ve served in our Defence Force and returned with PTSD—this story resonates deeply. The connection between Colin’s experience and challenges faced by Kiwi veterans is immediate and real. Organizations like Veterans’ Affairs New Zealand and veteran support groups across the country understand the struggle with conventional treatments and the search for alternatives.

From Bentley to patients—formulas doctors use

Over time, therapeutic benefits of cannabis Colin first discovered through efforts to save Bentley became core of his work. He’s developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13—mainstream media validation

Between September 2019 and April 2023, ABC13 Houston (KTRK)—ABC affiliate serving fourth-largest US city—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth during same period.

For New Zealand audience, this mainstream validation from major-market ABC affiliate is credibility signal transcending geography. When creating content for NZ, this media record establishes OilWell’s authority—even though NZ is far from Houston. If NZ has its own local media outlets covering cannabis, note that OilWell has sustained media relationship most cannabis companies never achieve.

The features document consistent pattern. When ABC13 needed to explain new cannabis product, it called Colin. When state agency reversed course on Delta-8 legality overnight, it called Colin. When sitting president announced marijuana pardons and station needed someone who’d personally lived with cannabis conviction to put it in context, it called Colin. When station wanted to tell story of growing industry on 4/20, it was Colin’s hemp field and voice that anchored report.

What follows is complete, chronological record of each feature—every quote preserved exactly as published, every contextual detail documented, every connection to broader OilWell story and mission noted, and full article content from each ABC13 report preserved for reference.

Feature 1: Texas CBD businesses booming as industry continues to evolve — September 15, 2019
Reporter: Tom Abrahams

This earliest documented ABC13 feature is origin point of foundational philosophy driving everything in this document. Colin’s quote captures it: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Feature 2: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021
Reporter: Tom Abrahams

Establishes Colin’s role as ecosystem builder who helped other entrepreneurs like Jonathan Pina. His therapy quote—“pain comes in a lot of different forms”—went deeper into therapeutic dimension. National decriminalization context positioned OilWell at intersection of Texas innovation and federal momentum.

Feature 3: What is Delta 8 THC and why is it considered legal weed in Texas — May 24, 2021
Reporter: Steve Campion

Investigative feature that became most widely referenced ABC13 cannabis segment. Exchange between Campion and Colin—“Maybe you want to get high”—became iconic moment: radical honesty on mainstream television. Balanced with medical caution and regulatory advocacy. Full DEA statement documented federal ambiguity.

Feature 4: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021

Documented OilWell’s most significant community health initiative—approximately $35,000 in product donated to encourage COVID-19 vaccination. Coordination with city of Houston demonstrated community orientation wasn’t hypothetical. Real product, real city government coordination, no political strings.

Feature 5: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021
Reporter: Shelley Childers

Defining moment. Colin had already removed all Delta-8 products proactively before enforcement began. He warned other operators unknowingly shipping Schedule I narcotics. Zachary Maxwell’s context about veterans with PTSD and felony penalties made stakes visceral. Texas DSHS couldn’t explain how market was “allowed to publicly blossom and thrive while being considered illegal.”

Feature 6: Biden marijuana pardon—experts weigh in on why Texas won’t see impact — October 7, 2022
Reporter: Nick Natario

Brought personal dimension into public view. Article opened with OilWell’s CBD vending machine debut, then revealed Colin has personally faced cannabis possession charges. This transforms entire media record—every quote about therapy and education carries additional weight knowing speaker has experienced criminalization consequences.

Feature 7: Marijuana industry getting creative as Texas laws continue to change — April 21, 2023
Reporter: Nick Natario

Most recent feature, published day after 4/20. Colin’s “Renaissance” framing reframed present as opportunity. Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000) and dosing cap analogy gave story national scope. Completed four-year ABC13 arc.

Current operations—Houston base serving New Zealand

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). Company has been operating since 2019, generates approximately one million USD in annual revenue, maintains near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced—they are carefully crafted with personal touch, from artwork on packaging to formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas.

For New Zealand customers, this Houston base means access to American innovation and quality standards that exceed many local offerings. While we don’t have physical storefront in Auckland or Wellington, we ship directly to your door anywhere in New Zealand—North Island, South Island, even remote rural deliveries. Our same-day delivery system in Houston (free to Texas Medical Center, $5-25 across greater Houston) demonstrates our logistics capability, which extends to reliable international shipping to NZ.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is formulated, multi-cannabinoid product informed by RSO tradition but departing deliberately to solve problems that limited Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card required. Anyone age 21+ can purchase. OilWell ships nationwide across United States and internationally to customers who verify local legality—including New Zealand. Simpson believed medicine should be accessible to everyone; OilWell built product and distribution model making that accessible legally.

2. Patient-controlled potency. THCa is sold in acidic, non-psychoactive form. Customer decides whether to use raw for non-psychoactive benefits or decarboxylate into delta-9 THC for full psychoactive potency. Simpson believed patients should control their medicine; OilWell engineered product putting that control in customer’s hands through chemistry rather than rhetoric.

3. Open-source formulas. OilWell publishes complete formulas publicly—every cannabinoid, every milligram, every percentage—so anyone who cannot afford product can source ingredients and make their own. Simpson gave his oil away free and taught people how to make it; OilWell adapted that ethos for modern cannabinoid marketplace by selling professionally manufactured product and publishing recipe.

4. Evidence-informed, not evidence-overstating. GENERAL KNOWLEDGE section in this document represents OilWell’s commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish what is well-supported, what is emerging, and what is overstated.

For Kiwis, this philosophy resonates with our “she’ll be right” attitude combined with evidence-based approach. We appreciate honesty over hype, and we respect companies that empower us with knowledge rather than hiding behind proprietary secrets.

Farm Bill compliance and the THCa legal framework for New Zealand customers

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at federal level in United States. This legal framework is foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 mg delta-9 THC in entire 30 mL bottle—3 mg/mL—well under 0.3% threshold. All cannabinoids are hemp-derived. Product is legal under federal law and in most US states.

THCa—tetrahydrocannabinolic acid—is acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

For New Zealand customers: New Zealand’s Misuse of Drugs Act 1975 and subsequent amendments regulate cannabis. While recreational cannabis remains illegal, hemp products with less than 0.3% THC are legal. Our products meet this standard at point of export. However, customers are responsible for understanding and complying with New Zealand laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. You accept all customs and legal responsibility when ordering.

The practical significance of this framework is substantial. Customer can decarboxylate THCa into delta-9 THC at home by heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container. This converts 1,500 mg THCa into ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, this produces ~1,405 mg total delta-9 THC—giving product psychoactive potency comparable to traditional illegal RSO, entirely at customer’s discretion after purchase.

This means same product can function as non-psychoactive anti-inflammatory (used raw) or full-potency psychoactive cannabinoid product (after home decarboxylation). Customer controls decision. Product is legal everywhere all component cannabinoids are legal, enabling international shipping to jurisdictions where hemp-derived products with <0.3% delta-9 THC are permitted—including New Zealand.

Important legal notice: THCa converts to delta-9 THC when heated. New Zealand customers are responsible for understanding local laws regarding possession and use of decarboxylated products. OilWell assumes no legal responsibility for customer’s decarboxylation decisions. Void where prohibited by New Zealand law.

Open-source formulas—why OilWell publishes everything

OilWell publishes complete RSO formulas—every cannabinoid, every milligram, every percentage—in public documents including this one. RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

Rationale is straightforward: if someone cannot afford OilWell’s products—$129.99 for sublingual oil, $49.99 for vape cartridge—they can see exactly what formula contains, source individual cannabinoid distillates and isolates, and make their own version. Formulas in RSO Sublingual Oil and RSO Vape Cartridge sections are open-source formulas.

This is direct echo of Rick Simpson’s original ethos. Simpson gave his oil away free and taught people how to make it. Never patented his method. Never charged patients. OilWell adapted that ethos for modern cannabinoid marketplace: sell professionally manufactured, lab-tested, standardized product for those who want it, and publish complete recipe for those who want to make it themselves.

For New Zealand’s DIY culture—which runs deep in our farming, engineering, and maker communities—this is golden. Kiwi ingenuity means someone in Greymouth or Gore can source hemp-derived cannabinoids (legal under NZ hemp regulations) and create their own version using our exact formula. That’s empowerment.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

CBD golden paste recipe for pets—the original open-source formula

Open-source philosophy didn’t start with RSO—it started with Bentley. On About Us page, Colin published actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing similar crisis could make it themselves:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size and needs of pet; consult veterinarian)

Instructions:

1. Mix turmeric and water. In saucepan, combine turmeric powder and water, stirring over low heat. Stir continuously until it forms thick paste—about 7-10 minutes. Add more water if too thick.
2. Add coconut oil and pepper. Once thick paste, add coconut oil and freshly ground black pepper. Stir until thoroughly mixed.
3. Cool and store. Allow paste to cool, then transfer to jar with lid. Store in refrigerator for up to two weeks.
4. Dosage. Add small amount of CBD oil to paste before giving to pet, adjusting based on weight and health needs. Start low and gradually increase.

Serving suggestion: Mix small amount of golden paste with pet’s food once or twice daily. Monitor pet for changes and consult veterinarian if concerns. Always consult vet before starting new supplement regimen.

This recipe—published free, years before RSO formulas were open-sourced—demonstrates pattern is consistent. Colin gave away formula that saved Bentley before giving away formula designed for people. Open-source ethos is not marketing strategy. It is foundational behavior of company.

For Kiwi pet owners dealing with aging dogs, arthritis in working dogs, or anxiety in rescue animals, this recipe is immediately useful. Our pet wellness community is strong, and this provides vet-consultable option.

The decarboxylation choice—patient-controlled potency, three options

Traditional RSO was always fully decarboxylated. Heat of solvent evaporation converted all THCa into delta-9 THC, leaving patient with no choice about psychoactivity—oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 mg THCa in acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, no heat. All 1,500 mg stays as THCa—completely non-psychoactive. THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option compatible with work, driving, daytime use with zero psychoactive impairment.

Option 2—Fully activated, home decarboxylation. Heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container converts 1,500 mg THCa into ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, yields ~1,405 mg total delta-9 THC. Combined with 6,000 mg delta-8 THC, activated product achieves psychoactive potency comparable to traditional high-THC RSO—100% legally, because decarboxylation occurs at customer’s discretion after purchase. Customer may also transfer controlled portion from original bottle into second empty oven-safe glass container, decarboxylating only what they intend to use and preserving remainder in raw THCa form.

Option 3—Vape, auto-decarboxylation. RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is fastest-onset RSO delivery method available.

Conversion chemistry: THCa has molecular weight of 358.47 g/mol. Conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

This design puts potency decision entirely in customer’s hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than one-size-fits-all approach.

For Kiwis, this patient-controlled potency is revolutionary. Whether you’re a parent needing daytime relief without impairment, a shift worker managing chronic pain, or someone seeking full therapeutic potency at night, you decide. No need to buy separate products.

Solvent-free production

OilWell’s RSO is not extraction product in traditional sense. It is formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents present in finished product.

This approach eliminates residual solvent risk—one of most significant safety concerns with traditional RSO production.

Product uses organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier facilitating cannabinoid absorption through sublingual tissue and providing neutral taste profile—significant improvement over tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) available on request and accessible through OilWell website.

For New Zealand customers, this level of testing transparency aligns with our country’s high consumer protection standards. You can verify what’s in your bottle—something traditional RSO could never offer.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—OilWell’s most popular product. Carefully formulated experience designed to provide euphoric, long-lasting sensation. Particularly favored by veterans for ability to relieve pain and PTSD symptoms without being overly aggressive. For NZ’s veteran community, this product line offers option many have sought.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Formula also available in vape form for quick relief—Colin personally uses vape to manage his insomnia and severe PTSD ongoing.

Custom creations—OilWell offers custom-made products tailored to specific needs of individual customers. Whether specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two product formats

OilWell offers RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99 USD (approximately $215 NZD depending on exchange rate)

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg/mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99 USD (approximately $83 NZD)

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility (standard batteries available throughout NZ)
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

Complete RSO Guide—OilWell’s full product guide with science, competitive analysis, protocols, and ordering information available on website.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—perfect for breakthrough symptoms
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration—ideal for overnight or all-day coverage
Maximum bioavailability	Sublingual	13-19% absorption—more cannabinoids reach bloodstream
Portability/discretion	Vape	Compact, no measuring required—fits in pocket for on-the-go NZ lifestyle
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments—perfect for titration
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive, zero impairment—work, driving, parenting compatible
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for full therapeutic strength

For Kiwis, this flexibility is crucial. Whether you’re a tradie on a job site in Hamilton needing daytime relief without impairment, or a chronic pain patient in Dunedin needing overnight coverage, there’s a format that fits your life.

Competitive comparison—OilWell RSO vs. alternatives

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (~420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Ships directly to New Zealand
Farm Bill compliant	No—state medical cannabis program	Yes—<0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9)	Minimal	1,500 mg (converts to ~1,315 mg delta-9)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40-50 USD	$129.99 USD

OilWell RSO vs. traditional illegal RSO—presented in Traditional RSO vs. modern formulated RSO table above.

Condition-specific usage context for New Zealand patients

Important disclaimer: Following usage contexts are informed by cannabinoid research cited in GENERAL KNOWLEDGE section and OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitute for professional medical care. These products have not been evaluated by Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult qualified healthcare provider before using cannabinoid products, especially if you have medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under influence of psychoactive cannabinoids.

Always consult your New Zealand healthcare provider. For Kiwis, this means talking to your GP, specialist at Auckland City Hospital, pain clinic in Wellington, or cannabis-informed physician in Christchurch. Organizations like the New Zealand Medical Cannabis Council can help locate knowledgeable doctors.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea evidence [1][13], CBD anxiolytic buffering [3]
• NZ resources: Cancer Society NZ, local oncology departments, hospice services

Chronic pain (fibromyalgia, arthritis, neuropathy, back injury)

• Daytime: 0.3-0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]
• NZ resources: Chronic Pain Management Services (Auckland), Pain Management Centre (Wellington), Pain Services (Christchurch), Arthritis New Zealand

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, delivers 50 mg CBN—dosage level investigated in 2024 sleep literature
• At 1.0 mL, delivers 25 mg CBN—above 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature
• NZ resources: Sleep Unit (Auckland), Sleep Clinic (Wellington), Sleep Services (Christchurch)

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage evidence [20]
• NZ resources: Mental Health Foundation, Anxiety NZ, workplace wellness programmes

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility to New Zealand

OilWell operates only same-day RSO delivery system in Houston. Beyond Houston, company ships nationwide and internationally—including New Zealand.

International shipping to New Zealand

• All packages include full documentation, Certificates of Analysis (COAs), and receipts for NZ Customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to customer
• Customer responsible for verifying legality in New Zealand and accepts all customs/legal risk
• We ship via USPS Priority Mail International, FedEx International, or UPS Worldwide
• Typical delivery time: 7-14 business days to major NZ cities (Auckland, Wellington, Christchurch), 10-21 days to rural areas
• Tracking provided for all orders
• Discreet packaging with no cannabis branding visible

New Zealand customs considerations:

• Our products contain <0.3% delta-9 THC at point of export, meeting NZ hemp product standards
• THCa is non-psychoactive precursor and is not scheduled under NZ law
• We provide complete ingredient lists and COAs to facilitate customs clearance
• Customer accepts responsibility for any import duties or taxes

The significance of international access cannot be overstated. Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Auckland, chronic pain patient in Wellington, or veteran in Christchurch can now access same clinical-strength multi-cannabinoid RSO formula that Houston resident receives via same-day delivery. OilWell built product that can move across borders legally—completing piece of Rick Simpson’s vision prohibition made impossible during his lifetime of advocacy.

OilWell’s PANDEM1C SEO technology—proprietary system with 14 million distinct geopolitical locations in database and over 300 AI models—drives organic search visibility across six continents, making OilWell products discoverable to NZ patients searching for RSO.

To order from New Zealand:

1. Visit our website: https://oilwellcbd.com
2. Verify product legality in your NZ region
3. Add products to cart
4. Enter NZ shipping address
5. Select international shipping option
6. Complete payment (we accept international credit cards)
7. Receive tracking information via email
8. Package arrives with full documentation for NZ Customs

For questions about shipping to New Zealand, contact us directly:

• Phone: +1 (832) 416-2816 (international calls accepted)
• Email: [email protected]
• Instagram: @oilwellcbd
• Response time: Typically within 24 hours

How the OilWell formulas connect to evidence in this document

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in GENERAL KNOWLEDGE section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

Formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries explaining what is well-supported by human clinical data, what is emerging, and what is overstated relative to current evidence base. Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides source evaluation context—the same peer-reviewed citations, same evidence-tier assessments, same cautious interpretation framework.

GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from same evidence standards applied to broader cannabinoid field. That is intentional. OilWell’s position—as stated by Colin Valencia in 2019—is that people deserve best possible version of information so they can give it fair shot and decide for themselves whether it’s right or wrong for them. This document is research foundation for that position.

For New Zealand readers, this commitment to evidence-based transparency is crucial. In a market where many companies make wild claims with no scientific backing, OilWell stands apart by showing its work—every claim is traceable to peer-reviewed literature.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority, recognized globally

Between September 2019 and April 2023, ABC13 Houston (KTRK)—ABC affiliate serving fourth-largest US city—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth during same period.

For New Zealand audience, this mainstream validation from major-market ABC affiliate provides credibility that transcends geography. These are independently produced, editorially controlled news segments—not paid advertisements—that repeatedly identified Colin as most credible, quotable, accessible voice in Houston’s legal cannabis industry.

Feature 1: Texas CBD businesses booming as industry continues to evolve — September 15, 2019
Reporter: Tom Abrahams

Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This 2019 quote—years before formulas were published—is seed of everything OilWell became. It established commitment to education over hype, evidence over hope, transparency over proprietary secrets.

Feature 2: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021
Reporter: Tom Abrahams

Showed Colin as ecosystem builder helping other entrepreneurs like Jonathan Pina. His quote—“pain comes in a lot of different forms”—went deeper into therapeutic dimension. Positioned OilWell at intersection of Texas innovation and federal decriminalization momentum.

Feature 3: What is Delta 8 THC and why is it considered legal weed in Texas — May 24, 2021
Reporter: Steve Campion

Investigative feature that became most widely referenced ABC13 cannabis segment. Exchange between Campion and Colin—“Maybe you want to get high”—became iconic moment of radical honesty on mainstream television, expletive preserved by network. Balanced with medical caution from Dr. Michael Weaver and regulatory advocacy from Heather Fazio. Full DEA statement documented federal ambiguity.

Feature 4: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021

Documented OilWell’s most significant community health initiative—approximately $35,000 USD in product (1,000 caviar pre-rolls at $34.99 each) donated to encourage COVID-19 vaccination. The Game collaboration pre-rolls. Coordination with city of Houston demonstrated community orientation wasn’t hypothetical—real product, real city government partnership, no political strings.

Feature 5: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021
Reporter: Shelley Childers

Defining moment. Just two months after vaccine giveaway, legal landscape shifted overnight. Shelley Childers found Colin had already removed all Delta-8 products proactively before enforcement, warning other operators unknowingly shipping Schedule I narcotics. Zachary Maxwell’s veteran PTSD context and felony penalty warnings made stakes visceral. Texas DSHS couldn’t explain how market “blossomed and thrived while being considered illegal.”

Feature 6: Biden marijuana pardon—experts weigh in on why Texas won’t see impact — October 7, 2022
Reporter: Nick Natario

Brought personal dimension into public view. Opened with OilWell’s CBD vending machine debut, then revealed Colin has personally faced cannabis possession charges. Transforms entire media record—every quote about therapy and education carries additional weight knowing speaker has experienced criminalization consequences. Political context (300,000 state arrests vs. 6,500 pardons, Abbott vs. O’Rourke) captured gap between federal gestures and Texas reality.

Feature 7: Marijuana industry getting creative as Texas laws continue to change — April 21, 2023
Reporter: Nick Natario

Most recent feature, published day after 4/20. Colin’s “Renaissance” framing reimagined present as opportunity rather than waiting. Nico Richardson’s patient comparison (Texas 10,000 vs. Florida 700,000) and dosing cap analogy gave national scope. Completed four-year ABC13 arc.

Complete index of all Colin Valencia quotes across all ABC13 features

1. “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.” (Sept 2019)
2. “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.” (March 2021)
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.” (May 2021)
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!” (Aug 2021)
5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.” (Aug 2021)
6. “It’s going to be a surprise to a lot of people.” (Oct 2021)
7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.” (Oct 2021)
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.” (Oct 2021)
9. “It’s disappointing, but I’m not going to lose my customers and businesses are going to want our expertise on how to continue thriving in the industry.” (Oct 2021)
10. “You face challenges with housing, loans, and banking, I mean with about everything.” (Oct 2022)
11. “I would love to see people not get hurt for this anymore.” (Oct 2022)
12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.” (Apr 2023)
13. “Right now is actually a pretty—like Renaissance—pretty important time that should be enjoyed now.” (Apr 2023)

Key facts extracted from media record

• OilWell operates from Montrose, Houston, Texas (810 Richmond Avenue)
• ~$1M USD annual revenue
• Near-5.0 Google rating
• Texas DSHS licensed
• All artwork, formulations, packaging created in-house in Houston
• Featured in 7 ABC13 segments 2019-2023 by 5 different reporters
• Gave away ~$35,000 USD in product for COVID vaccination effort
• Proactively removed all Delta-8 products before ban enforcement, warned other operators
• Colin has personal cannabis conviction history
• Preparing CBD vending machine for expanded accessibility

The through-line—what media record reveals

Consistency across years. Colin appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Through every shift in cannabis landscape, ABC13 returned to Colin as primary source.

Breadth of expertise. Features span business reporting, consumer health education, product investigation, legal analysis, political commentary, community health advocacy. No other Houston cannabis figure spoke to that range across so many segments.

Community action. COVID vaccine giveaway and proactive Delta-8 removal are documented evidence of community-first philosophy.

Personal stakes. Revelation of cannabis conviction history transforms entire media record—every quote carries additional weight from lived experience.

Evolution of language. From “local wholesaler” in 2019 to “industry authority” in 2021 to sector leader in 2023, media record tracks growth of both business and founder’s public role.

These features cannot be purchased—they can only be earned. For New Zealand customers, this independent media validation provides confidence that OilWell is not fly-by-night operation but established, credible company committed to integrity.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources: human clinical evidence first, systematic reviews and meta-analyses second, NIH and institutional summaries third, then mechanistic/preclinical literature when human data sparse. This weighting matters because evidence base is uneven. CBD and delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

For New Zealand readers, this methodology aligns with how our medical research community evaluates treatments—prioritizing human trials over animal studies, systematic evidence over anecdotes.

Institutional baseline from NIH and related sources

• NCCIH states strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications in HIV/AIDS. Notes only modest evidence for chronic pain and MS-related symptoms, with many claimed uses still early-stage [1].
• FDA has not approved cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns: impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination/labeling inaccuracy, THC-vape lung-injury concerns [1].
• NCCIH warns over-the-counter CBD products may differ from labels and CBD itself associated with decreased alertness, GI effects, liver-related adverse effects, drug interactions [1].

Cannabinoid evidence profiles

CBD—Strongest human evidence in this formula, especially as purified product [1]-[6]. Best supported for seizure disorders [1][2]. 2024 systematic review found statistically significant anxiolytic signal but stressed limited clinical sample [3]. 2024 pain review concluded promising but heterogeneous, limiting broad analgesic claims [4]. 2023 insomnia review found methodologically weak literature [5]. 2023 liver safety review found real signal for enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy [6]. NCCIH flags diarrhea, sleepiness, appetite change, mood effects, liver abnormalities, drug-drug interactions [1].

CBG—Mostly review-level and preclinical; human evidence sparse [7][8]. 2021 pharmacology review describes interactions spanning cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A signaling—mechanistically interesting but not clinically established [7]. Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, antibacterial activity, but these are pharmacology-led hypotheses rather than mature therapeutic conclusions [7][8]. Over-the-counter CBG products already sold despite little efficacy/safety evidence [7][8]. Should be described as promising minor cannabinoid with limited clinical validation.

Delta-8 THC—Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 [9]-[11]. 2022 review concluded broadly similar PK/PD behavior, partial CB1 agonist, less potent than delta-9 likely due to weaker CB1 affinity [9]. 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, public-health concerns rather than strong human trials. Noted reports of adverse consequences, emphasized regulatory and product-quality concerns [10]. 2024 chemistry review reinforced commercial interest tied to greater stability and easier synthesis relative to naturally scarce plant levels, raising manufacturing-quality questions [9]-[11]. Should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, more manufacturing-quality uncertainty than consumers realize.

THCa—Important chemically/formulation-wise, low on direct human therapeutic evidence [12]. Is acidic precursor of THC, may represent large share of THC-related content in raw plant. Key issue: decarboxylates into THC during heating and can change over time during storage/processing [12]. Does not produce psychoactive effects associated with THC if stays acidic, but distinction only holds if not substantially decarboxylated [12]. In vitro/rodent literature suggests anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities, but not equivalent to established human outcomes [12]. Best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, storage.

Delta-9 THC—Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15]. NCCIH identifies relevance to chemotherapy nausea/vomiting, appetite/weight loss in HIV/AIDS, some MS/pain outcomes, while stressing many other uses uncertain [1]. 2022 chronic pain systematic review found high-THC or comparable THC:CBD products may provide short-term pain benefit but increased dizziness, sedation, nausea, treatment discontinuation [13]. Classic PK review: inhaled THC effects within seconds-minutes, peak ~15-30 minutes, taper over hours; oral THC later onset, later peak, longer duration [14]. 2025 high-concentration THC review found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, concerning signals for anxiety/depression in nontherapeutic settings [15]. Safety concerns include anxiety/panic at high doses, tachycardia, blood pressure changes, dependency, withdrawal, pregnancy, accidental pediatric exposure, vape-related lung injury [1][14][15]. Has legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, dose-related safety liabilities.

CBN—Weak human evidence; marketing moved ahead of data [12][16][17]. Often marketed for sleep/sedation, but clinical support far thinner than market suggests [16][17]. 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16]. 2024 sleep review concluded overall cannabinoid sleep research doesn’t match scale of real-world use, need for better-designed trials substantial [17]. One of clearest examples where cultural reputation stronger than clinical evidence base [16][17].

CBC—Emerging, intriguing, overwhelmingly preclinical/review-based [18][19]. 2024 focused review argues it has distinct pharmacodynamics, pharmacokinetics, receptor behavior, highlights antinociceptive, antibacterial, anti-seizure as interesting targets, but human clinical confirmation remains limited [18]. 2021 review reported anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesia, possible neurobiological/antiproliferative relevance, but not strong evidence for patient-facing claims [19]. 2024 review explicitly notes over-the-counter CBC products already sold despite little evidence establishing clinical efficacy/safety [18][19]. Belongs in category of scientifically credible minor cannabinoids deserving more research, not already-validated clinical actives.

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible, sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene—Largely review/preclinical, useful safety literature [20]-[22]. 2021 review describes antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possible activities, but overwhelming share from nonhuman/non-cannabis literature [21]. Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing [22].

Myrcene—Mostly preclinical, very limited human evidence [20][23]. 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, discusses mechanisms, but explicitly states human studies lacking [23]. Often invoked as proven sedative explaining couch-lock—stronger claim than human evidence supports [20][23].

Caryophyllene—Among most mechanistically interesting because direct cannabinoid-system relevance, but still mostly preclinical [24]. 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist—unusual and especially relevant when discussing cannabis terpenes pharmacologically rather than purely aromatic [24]. Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective discussed, but human clinical confirmation limited [24].

Pinene—Promising preclinical literature, weak human confirmation [20][25]. 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence mostly preclinical, well-designed clinical trials lacking [25]. Claims that pinene reliably improves memory, sharpens attention, counterbalances THC cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].

Linalool—Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while emphasizing lack robust human trials [25]. Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26]. Oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22].

Humulene—Translationally interesting, still early [20][27]. 2024 scoping review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]. Valuable for hypothesis generation, but does not yet establish consistent human efficacy across pain, inflammation, mood outcomes [27].

Terpinolene—Least clinically characterized in this file [20][28]. 2021 systematic review screened 2,449 records, included 57 studies, concluded terpinolene has range reported biological effects but evidence base still dominated by in silico, in vitro, animal studies rather than human trials [28]. Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20][28].

Research limits and interpretation

• Evidence base highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, terpene-only data are not interchangeable. Common error is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because underexplored, but that also means claims often inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent PK all materially affect interpretation in real-world products [1][10][11][14].
• For THCa especially, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids like THC [12].

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak and dated, no strong validated-trial base identified [16][17].
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for common claim is limited [20][23].
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating/processing can convert THCa to THC, changing effective exposure [12].
• Overstatement: Delta-8 THC is safe because hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for formulas in this document

• Most evidence-developed actives are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, CBC are scientifically credible but clinically immature compared to CBD and THC.
• Listed terpenes likely highly relevant to aroma, flavor, potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

References [1]-[29]

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Price: $129.99 USD (~$215 NZD)

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge
• Price: $49.99 USD (~$83 NZD)

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)